Clinical Trial Update: DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for DS-8201a in patients with HER2-positive cancers completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasm
• Gastric Adenocarcinoma

Drugs mentioned

• DS-8201a (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company | Conditions: Adenocarcinoma, Gastric, Neoplasm, Breast | Phase 1 | Status: COMPLETED | Results posted: 2021-06-14